These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21677546)

  • 21. Toker-cell pathology as a unifying concept.
    Fernandez-Flores A
    Histopathology; 2008 Jun; 52(7):889-91; author reply 891-2. PubMed ID: 18462365
    [No Abstract]   [Full Text] [Related]  

  • 22. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
    Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
    Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LEA.135 expression: identifies low-risk patients with breast ductal carcinoma in situ.
    Baltayan A; Naritoku WY; Chaiwun B; Tsao-Wei DD; Groshen S; Hern RA; Gusterson BA; Taylor CR; Imam SA
    Anticancer Res; 2002; 22(5):2933-7. PubMed ID: 12530020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low PBRM1 identifies tumor progression and poor prognosis in breast cancer.
    Mo D; Li C; Liang J; Shi Q; Su N; Luo S; Zeng T; Li X
    Int J Clin Exp Pathol; 2015; 8(8):9307-13. PubMed ID: 26464681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications.
    Acs G; Lawton TJ; Rebbeck TR; LiVolsi VA; Zhang PJ
    Am J Clin Pathol; 2001 Jan; 115(1):85-98. PubMed ID: 11190811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Expression of Twist, E-cadherin and N-cadherin in breast carcinoma and their clinical significance].
    Ma YH; Wang K; Li L; Lu ZH; Chen J
    Zhonghua Bing Li Xue Za Zhi; 2010 Jan; 39(1):5-9. PubMed ID: 20388391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of Ki-67 and MCM-2 proliferative marker expression with grade of histological malignancy (G) in ductal breast cancers.
    Wojnar A; Kobierzycki C; Krolicka A; Pula B; Podhorska-Okolow M; Dziegiel P
    Folia Histochem Cytobiol; 2010 Sep; 48(3):442-6. PubMed ID: 21097442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MIB-1 Cell membrane reactivity: a finding that should be interpreted carefully.
    Del Sordo R; Sidoni A
    Appl Immunohistochem Mol Morphol; 2008 Dec; 16(6):568. PubMed ID: 18800001
    [No Abstract]   [Full Text] [Related]  

  • 29. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade.
    Mommers EC; Leonhart AM; Falix F; Michalides R; Meijer CJ; Baak JP; Diest PJ
    J Pathol; 2001 Jul; 194(3):327-33. PubMed ID: 11439365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nm23 expression in breast ductal carcinomas: a ten year follow-up study in a uniform group of node-negative breast cancer patients.
    Kapranos N; Karaiossifidi H; Kouri E; Vasilaros S
    Anticancer Res; 1996; 16(6C):3987-90. PubMed ID: 9042324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlations of bcl-2 expression with clinicopathological features in breast cancer.
    Lee HD; Koo JY; Jung WH
    Yonsei Med J; 1997 Aug; 38(4):206-11. PubMed ID: 9339128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients.
    van Nes JG; de Kruijf EM; Putter H; Faratian D; Munro A; Campbell F; Smit VT; Liefers GJ; Kuppen PJ; van de Velde CJ; Bartlett JM
    Breast Cancer Res Treat; 2012 May; 133(1):49-59. PubMed ID: 21796367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pathology of ductal carcinoma in situ of the breast.
    Bobrow LG; Millis RR
    Clin Oncol (R Coll Radiol); 1995; 7(4):232-5. PubMed ID: 8845318
    [No Abstract]   [Full Text] [Related]  

  • 34. Quantitative immunoprofiles of breast cancer performed by image analysis.
    Querzoli P; Albonico G; Ferretti S; Rinaldi R; Magri E; Nenci I
    Anal Quant Cytol Histol; 1999 Apr; 21(2):151-60. PubMed ID: 10560485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal antibody to thyroid transcription factor-1: production, characterization, and usefulness in tumor diagnosis.
    Holzinger A; Dingle S; Bejarano PA; Miller MA; Weaver TE; DiLauro R; Whitsett JA
    Hybridoma; 1996 Feb; 15(1):49-53. PubMed ID: 9064286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular markers and therapeutic targets in ductal carcinoma in situ.
    Boland GP; Knox WF; Bundred NJ
    Microsc Res Tech; 2002 Oct; 59(1):3-11. PubMed ID: 12242692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Breast ductal carcinoma in situ with microinvasion: pathological review and clinical implications].
    Modesto A; Gandy C; Mery E; Filleron T; Massabeau C; Izar F; Charitansky H; Roché H; de Lafontan B
    Cancer Radiother; 2014 Mar; 18(2):107-10. PubMed ID: 24637020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigation of immunohistochemical ERα, ERβ and ERβcx expressions in normal and neoplastic breast tissues.
    Bozkurt KK; Kapucuoğlu N
    Pathol Res Pract; 2012 Mar; 208(3):133-9. PubMed ID: 22336175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum erbB-2 in ductal carcinoma in situ of the breast--a marker of microinvasion?
    Esteva-Lorenzo FJ; Paik S; Harris LN
    Acta Oncol; 1997; 36(6):651-2. PubMed ID: 9408158
    [No Abstract]   [Full Text] [Related]  

  • 40. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer.
    Goldhirsch A; Glick JH; Gelber RD; Coates AS; Senn HJ
    J Clin Oncol; 2001 Sep; 19(18):3817-27. PubMed ID: 11559719
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.